Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

COVID-19: Post-hospital Thromboprophylaxis A multicenter, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge (ACTIV-4C)

ABSTRACT: COVID-19: Post-hospital Thromboprophylaxis A multicenter, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge (ACTIV-4C)

PROVIDER: PRJNA881453 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

COVID-19: Post-hospital Thromboprophylaxis A multicenter, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge (ACTIV-4C)

Project description:COVID-19: Post-hospital Thromboprophylaxis A multicenter, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge (ACTIV-4C)

| PRJNA881454 | ENA

Abnormal thrombosis and neutrophil activation increase hospital-acquired sacral pressure injuries and morbidity in COVID-19 patients

Project description:Characterization of the transcriptional signatures of 771 human genes and 19 coronavirus genes in skin samples collected from the borders of hospital-acquired sacral pressure injuries (HASPIs) that developed in individuals with and without COVID-19. Samples included pressure ulcers from individuals without COVID-19 (10), pressure ulcers from individuals with COVID-19 (5), as well as pressure ulcers with thrombotic vasculopathy histopathology from individuals with COVID-19 (8).

2023-04-12 | GSE214647 | GEO

COVID-19 ACTIV-4 ACUTE: Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV4A)

Project description:COVID-19 ACTIV-4 ACUTE: Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV4A)

| PRJNA781333 | ENA

COVID-19 ACTIV-4 ACUTE: Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV4A)

Project description:COVID-19 ACTIV-4 ACUTE: Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV4A)

| PRJNA781336 | ENA

COVID-19 Outpatient Thrombosis Prevention Trial ACTIV-4:A multicenter adaptive randomized placebo-controlled platform trial evaluating efficacy and safety of antithrombotic strategies in COVID-19 adults not requiring hospitalization at diagnosis (ACTIV4B)

Project description:COVID-19 Outpatient Thrombosis Prevention Trial ACTIV-4:A multicenter adaptive randomized placebo-controlled platform trial evaluating efficacy and safety of antithrombotic strategies in COVID-19 adults not requiring hospitalization at diagnosis (ACTIV4B)

| PRJNA783110 | ENA

| PRJNA783111 | ENA

ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications

Project description:ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications

| PRJNA1227597 | ENA

ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications

Project description:ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications

| PRJNA1227596 | ENA

Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae

Project description:Post-acute sequelae of COVID-19 (PASC) represent an emerging global crisis. However, quantifiable risk-factors for PASC and their biological associations are poorly resolved. We executed a deep multi-omic, longitudinal investigation of 309 COVID-19 patients from initial diagnosis to convalescence (2-3 months later), integrated with clinical data, and patient-reported symptoms. We resolved four PASC-anticipating risk factors at the time of initial COVID-19 diagnosis: type 2 diabetes, SARS-CoV-2 RNAemia, Epstein-Barr virus viremia, and specific autoantibodies. In patients with gastrointestinal PASC, SARS-CoV-2-specific and CMV-specific CD8+ T cells exhibited unique dynamics during recovery from COVID-19. Analysis of symptom-associated immunological signatures revealed coordinated immunity polarization into four endotypes exhibiting divergent acute severity and PASC. We find that immunological associations between PASC factors diminish over time leading to distinct convalescent immune states. Detectability of most PASC factors at COVID-19 diagnosis emphasizes the importance of early disease measurements for understanding emergent chronic conditions and suggests PASC treatment strategies.

2022-02-01 | E-MTAB-10129 | biostudies-arrayexpress

Human serum LC-MS/MS for long-term persistent COVID-19 patients

Project description:The emergence of a new type of COVID-19 patients, who were retested positive after hospital discharge with long-term persistent SARS-CoV-2 infection but without COVID-19 clinical symptoms (hereinafter, LTPPs), poses novel challenges to COVID-19 treatment and prevention. Why was there such a contradictory phenomenon in LTPPs? To explore the mechanism underlying this phenomenon, we performed quantitative proteomic analyses using the sera of 12 LTPPs (Wuhan Pulmonary Hospital), with the longest carrying history of 132 days, and mainly focused on seven LTPPs without hypertension (LTPPs-NH).

2022-10-22 | PXD036609 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data